Trial Details
COMPLETEDBasic Information
| Clinical ID | c2140 |
|---|---|
| Identifier | NCT03926130 |
| Trial Title | A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Mirikizumab|DRUG: Mirikizumab|DRUG: Ustekinumab|DRUG: Ustekinumab|DRUG: Placebo|DRUG: Placebo |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2019-07-23 |
|---|---|
| Primary Completion Date | 2023-08-23 |
| Completion Date | 2023-10-02 |